Compare ANTA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANTA | CGEN |
|---|---|---|
| Founded | 2022 | 1993 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.5M | 220.7M |
| IPO Year | 2025 | 2000 |
| Metric | ANTA | CGEN |
|---|---|---|
| Price | $9.00 | $2.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.50 | $4.00 |
| AVG Volume (30 Days) | 4.5K | ★ 591.3K |
| Earning Date | 11-10-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 669.18 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $65,033,103.00 | $6,903,000.00 |
| Revenue This Year | $69.27 | N/A |
| Revenue Next Year | $64.32 | $164.92 |
| P/E Ratio | $19.24 | ★ N/A |
| Revenue Growth | ★ 63.28 | N/A |
| 52 Week Low | $8.50 | $1.13 |
| 52 Week High | $27.72 | $2.66 |
| Indicator | ANTA | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 66.02 |
| Support Level | $9.00 | $2.04 |
| Resistance Level | $9.99 | $2.38 |
| Average True Range (ATR) | 0.31 | 0.15 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 22.59 | 73.64 |
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.